SEARCH

SEARCH BY CITATION

References

  • 1
    Roodman GD 1997 Mechanisms of bone lesions in multiple myeloma and lymphoma. Cancer 80(Suppl 8):15571563.
  • 2
    Choi SJ, Oba Y, Gazitt Y, Alsina M, Cruz J, Anderson J, Roodman GD 2001 Antisense inhibition of macrophage inflammatory protein 1-alpha blocks bone destruction in a model of myeloma bone disease. J Clin Invest 108:18331841.
  • 3
    Giuliani N, Bataille R, Mancini C, Lazzaretti M, Barille S 2001 Myeloma cells induce imbalance in the osteoprotegerin/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:35273533.
  • 4
    Pearse RN, Sordillo EM, Yaccoby S, Wong BR, Liau DF, Colman N, Michaeli J, Epstein J, Choi Y 2001 Multiple myeloma disrupts the TRANCE/osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci USA 98:1158111586.
  • 5
    Roux S, Meignin V, Quillard J, Meduri G, Guiochon-Mantel A, Fermand JP, Milgrom E, Mariette X 2002 RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol 117:8692.
  • 6
    Holmes JA, Evans WD, Coles RJ, Ramsahoye B, Whittaker JA 1994 Dual energy X-ray absorptiometry measurements of bone mineral density in myeloma [letter].Eur J Haematol. 53:309311.
  • 7
    Mariette X, Bergot C, Ravaud P, Roux C, Laval-Jeantet M, Brouet JC, Fermand JP 1995 Evolution of bone densitometry in patients with myeloma treated with conventional or intensive therapy. Cancer 76:15591563.
  • 8
    Kanis JA, Melton LJ III, Christiansen C, Johnston CC, Khaltaev N 1994 The diagnosis of osteoporosis. J Bone Miner Res 9:11371141.
  • 9
    Dhodapkar MV, Weinstein R, Tricot G, Jagannath S, Parfitt AM, Manolagas SC, Barlogie B 1998 Biologic and therapeutic determinants of bone mineral density in multiple myeloma. Leuk Lymphoma 32:121127.
  • 10
    Laroche M, Pouilles JM, Dromer C, Attal M, Ribot C 1996 Dual-energy X-ray absorptiometry in patients with multiple myeloma and benign gammopathies [letter].Clin Exp Rheumatol 14:108.
  • 11
    Diamond T, Levy S, Day P, Barbagallo S, Manoharan A, Kwan YK 1997 Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: Effects of glucocorticoid therapy and disease activity. Br J Haematol 97:641648.
  • 12
    Mariette X, Khalifa P, Ravaud P, Frija J, Laval-Jeantet M, Chastang C, Brouet JC, Fermand JP 1992 Bone densitometry in patients with multiple myeloma. Am J Med 93:595598.
  • 13
    Roux C, Ravaud P, Cohen-Solal M, de Vernejoul MC, Guillemant S, Cherruau B, Delmas P, Dougados M, Amor B 1994 Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma. Bone 15:4149.
  • 14
    Bataille R, Chappard D, Basle M 1995 Excessive bone resorption in human plasmacytomas: Direct induction by tumour cells in vivo. Br J Haematol 90:721724.
  • 15
    Taube T, Beneton MN, McCloskey EV, Rogers S, Greaves M, Kanis JA 1992 Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. Eur J Haematol 49:192198.
  • 16
    Parfitt AM, Mundy GR, Roodman GD, Hughes DE, Boyce BF 1996 A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res 11:150159.
  • 17
    Fleisch H 1998 Bisphosphonates: Mechanisms of action. Endocr Rev 19:80100.
  • 18
    Seidel C, Hjertner O, Abildgaard N, Heickendorff L, Hjorth M, Westin J, Nielsen JL, Hjorth-Hansen H, Waage A, Sundan A, Borset M 2001 Serum osteoprotegerin levels are reduced in patients with multiple myeloma with lytic bone disease. Blood 98:22692271.
  • 19
    Bataille R, Chappard D, Marcelli C, Dessauw P, Baldet P, Sany J, Alexandre C 1991 Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88:6266.
  • 20
    Hjorth-Hansen H, Seifert MF, Borset M, Aarset H, Ostlie A, Sundan A, Waage A 1999 Marked osteoblastopenia and reduced bone formation in a model of multiple myeloma bone disease in severe combined immunodeficiency mice. J Bone Miner Res 14:256263.
  • 21
    McDermott AY, Shevitz A, Knox T, Roubenoff R, Kehayias J, Gorbach S 2001 Effect of highly active antiretroviral therapy on fat, lean, and bone mass in HIV-seropositive men and women. Am J Clin Nutr 74:679686.